Can an experimental drug stop polyps from coming back in a rare inherited condition?

NCT ID NCT07729371

Not yet recruiting Disease control Sponsor: Sapience Therapeutics Source: ClinicalTrials.gov ↗

First seen Jul 27, 2026 · Last updated Aug 13, 2026 · Updated 5 times

Summary

This phase 1b trial tests an experimental drug called ST316 in adults with familial adenomatous polyposis (FAP) who have already had their colon removed but still develop new polyps. The study aims to see if ST316 is safe and can reduce the number and size of polyps that grow back. Participants receive ST316 intravenously at different schedules, and doctors monitor polyp burden and side effects over several months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: an experimental drug called ST316 given intravenously
What this could lead to: If successful, this could point toward a new treatment to control polyp regrowth and reduce the need for repeated surgeries in people with FAP.
What could go wrong: This is an early-phase trial with only 40 participants, so safety and effectiveness are not yet established. The drug may cause side effects or fail to reduce polyps.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAMILIAL ADENOMATOUS POLYPOSIS (FAP) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Adenomatous Polyposis Coli classic familial adenomatous polyposis desmoid tumor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAMILIAL ADENOMATOUS POLYPOSIS (FAP)

More trials for these conditions

Other studies related to the condition(s) this trial covers.